{"organizations": [], "uuid": "f9836adecb9ad22f3616025b615c844333a0624b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cipher-pharmaceuticals-acquires-ex/brief-cipher-pharmaceuticals-acquires-exclusive-canadian-rights-to-fda-approved-trulance-from-synergy-pharma-idUSFWN1QI0TN", "country": "US", "domain_rank": 408, "title": "BRIEF-Cipher Pharmaceuticals Acquires Exclusive Canadian Rights To FDA-Approved Trulance® From Synergy Pharma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.824, "site_type": "news", "published": "2018-02-28T20:11:00.000+02:00", "replies_count": 0, "uuid": "f9836adecb9ad22f3616025b615c844333a0624b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cipher-pharmaceuticals-acquires-ex/brief-cipher-pharmaceuticals-acquires-exclusive-canadian-rights-to-fda-approved-trulance-from-synergy-pharma-idUSFWN1QI0TN", "ord_in_thread": 0, "title": "BRIEF-Cipher Pharmaceuticals Acquires Exclusive Canadian Rights To FDA-Approved Trulance® From Synergy Pharma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cipher pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - Cipher Pharmaceuticals Inc:\n* CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO FDA-APPROVED TRULANCE® FROM SYNERGY PHARMACEUTICALS\n* CIPHER PHARMACEUTICALS INC - ‍UNDER TERMS OF LICENSING AGREEMENT, SYNERGY WILL RECEIVE AN UPFRONT PAYMENT OF US$5.0 MILLION​\n* CIPHER - ‍UNDER TERMS OF LICENSING AGREEMENT, SYNERGY ELIGIBLE FOR ADDITIONAL MILESTONE PAYMENT, & ROYALTIES FROM PRODUCT SALES IN CANADA​\n* CIPHER PHARMACEUTICALS INC - ‍AGREEMENT PROVIDES THAT SYNERGY WILL BE RESPONSIBLE FOR MANUFACTURING AND SUPPLYING FINISHED PRODUCT TO CO Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-28T20:11:00.000+02:00", "crawled": "2018-03-01T21:03:54.052+02:00", "highlightTitle": ""}